Use of Beta-agonists in Stable Severe Congestive Heart Failure

The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.

Inclusion Criteria:

• Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with a measured EF <35%, class III as defined by the NYHA with ICD and who receive optimal pharmacological therapy.

Exclusion Criteria:

• Heart Failure class I, II, IV
• atrial fibrillation
• any significant valvular disease
• chronic obstructive pulmonary disease who treated with inhaled β2 agonist
• significant kidney disease with eGFR <30%
• severe uncontrolled electrolyte abnormalities
• prior allergic reaction to Salbutamol
• Pregnancy and nursing women